BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26964779)

  • 1. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
    Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
    Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
    Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
    Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with
    Narsinh KH; Van Buskirk M; Kennedy AS; Suhail M; Alsaikhan N; Hoh CK; Thurston K; Minocha J; Ball DS; Cohen SJ; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kanani S; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA; Rose SC
    Radiology; 2017 Jan; 282(1):281-288. PubMed ID: 27440733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
    King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
    Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.
    Dabrowiecki A; Sankhla T; Shinn K; Bercu ZL; Ermentrout M; Shaib W; Cardona K; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1006-1014. PubMed ID: 32367230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
    Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
    Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases.
    Faron A; Pieper CC; Schmeel FC; Sprinkart AM; Kuetting DLR; Fimmers R; Trebicka J; Schild HH; Meyer C; Thomas D; Luetkens JA
    Eur Radiol; 2019 Sep; 29(9):4709-4717. PubMed ID: 30689036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
    Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
    Saxena A; Kapoor J; Meteling B; Morris DL; Bester L
    Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
    Jia Z; Wang W
    Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic
    Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H
    AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
    Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
    BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging Predictors of Elevated Lung Shunt Fraction in Patients Being Considered for Yttrium-90 Radioembolization.
    Olorunsola OG; Kohi MP; Behr SC; Kolli PK; Taylor AG; Tong RT; LaBerge JM; Kerlan RK; Fidelman N
    J Vasc Interv Radiol; 2015 Oct; 26(10):1472-8. PubMed ID: 26296737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.
    Gaba RC; Zivin SP; Dikopf MS; Parvinian A; Casadaban LC; Lu Y; Bui JT
    Radiology; 2014 May; 271(2):602-12. PubMed ID: 24533871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Hickey R; Kulik L; Desai K; Yang Y; Gates VL; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1213-1222. PubMed ID: 28280976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
    Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S
    Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
    Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
    Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
    Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.